Tag:
Algeta
Latest Headlines
Latest Headlines
Medivation surges as rivals aim at fast-changing prostate cancer market
Shares of Medivation ( $MDVN ) jumped 17% today after the drug developer confirmed some promising Phase III data on the closely-watched prostate cancer therapy MDV3100 and added some reassuring numbers
Bayer's blockbuster Alpharadin may roil fast-changing prostate cancer field
The experimental prostate cancer drug Alpharadin took center stage at the big EMCC meeting in Stockholm, with researchers reporting that they had suspended a registration trial after
Bayer, Algeta shares spike as FDA fast-tracks blockbuster hopeful
Bayer and its biotech partner Algeta took a big step today toward a relatively quick FDA decision on their closely-watched prostate cancer drug Alpharadin (radium-223 chloride). Regulators are
Algeta shares spike on promising prostate cancer drug data
Shares of Norway's Algeta spiked 36 percent this morning after the biotech's partner Bayer unveiled promising data on their castration-resistant prostate cancer treatment Alpharadin (radium-223
Bayer snares Algeta's lead cancer med in $800M pact
In a fresh sign of just how hot cancer meds have become, Bayer Schering Pharma took analysts by surprise this morning with an $800 million licensing pact for Algeta's lead drug--an experimental
U.S., Norwegian, Irish biotechs raise millions
There's a slate of new biotech investments on the wires this morning.
Abingworth has led an investment group which is injecting $35 million into Norway's Algeta. And the bulk of the money will go to
